FDA approves Dupixent as the first new CSU treatment in over a decade. 2. Phase 3 trial shows significant symptom reduction ...

New research from the Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai ...

Ashley Lora joined an eczema clinical trial for DUPIXENT and paved the way for other Black women to try clinical trials.

Despite increasing competition in established indications, Dupixent remains the market leader. In atopic dermatitis ... supply copay assistance in the form of a coupon, et cetera, et cetera.

Jason Hawkes, MD, MS, provided an in-depth look at the potential role of dupilumab (Dupixent ... several type 2 inflammatory diseases like atopic dermatitis and asthma and has demonstrated ...

HealthDay News — Midafternoon dosing with beclomethasone dipropionate is associated with better clinical outcomes in mild-to-moderate atopic asthma, according to a study published online April 15 in ...

Racial representation in recent atopic dermatitis trials has largely been ... “Without diverse enrollment, clinicians risk relying on trial data that may not reflect the treatment responses ...

In 2023, federal data revealed that its overall Black enrollment, 11 percent of the student body, far outstripped many other similar institutions. So it was particularly jarring to the Amherst ...

The company reported Q1 sales of Dupixent at 3.5 billion euros ($4 billion), which was an impressive increase of 20% year over year. In 2024, Dupixent sales came in at $14.1 billion, which was an ...

Sanofi SA reported better-than-expected profit in the first quarter, boosted by strong demand for its blockbuster skin and asthma drug Dupixent. Earnings per share, excluding some items, were €1.79 ...

With this FDA decision, Dupixent is now approved for seven chronic, debilitating atopic conditions driven in part by underlying type 2 inflammation, several of which have been shown to co-morbidly ...